Astrazeneca prepares and tests GLP-1R agonists for type 2 diabetes
April 28, 2023
A recent Astrazeneca AB patent describes 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of type 2 diabetes.